Lyell Immunopharma 55087PAB0 Bond
| LYEL Stock | USD 0.92 0.01 1.10% |
Lyell Immunopharma holds a debt-to-equity ratio of 0.077. At this time, Lyell Immunopharma's Net Debt To EBITDA is quite stable compared to the past year. Interest Debt Per Share is expected to rise to 0.30 this year, although the value of Short and Long Term Debt Total will most likely fall to about 61.8 M. . Lyell Immunopharma's financial risk is the risk to Lyell Immunopharma stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Lyell Immunopharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Lyell Immunopharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Lyell Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Lyell Immunopharma's stakeholders.
For most companies, including Lyell Immunopharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Lyell Immunopharma, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Lyell Immunopharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 0.4843 | Book Value 2.068 | Operating Margin -1.5 K | Return On Assets (0.19) | Return On Equity (0.33) |
Lyell |
Given the importance of Lyell Immunopharma's capital structure, the first step in the capital decision process is for the management of Lyell Immunopharma to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Lyell Immunopharma to issue bonds at a reasonable cost.
| Popular Name | Lyell Immunopharma US55087PAB04 |
| Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
| Equity ISIN Code | US55083R1041 |
| Bond Issue ISIN Code | US55087PAB04 |
| S&P Rating | Others |
| Maturity Date | Others |
| Issuance Date | 15th of May 2020 |
| Coupon | 1.5 % |
Lyell Immunopharma Outstanding Bond Obligations
| MPLX LP 52 | US55336VAL45 | Details | |
| Morgan Stanley 3591 | US61744YAK47 | Details | |
| US55087PAB04 | US55087PAB04 | Details |
Understaning Lyell Immunopharma Use of Financial Leverage
Leverage ratios show Lyell Immunopharma's total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of Lyell Immunopharma's financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 63.2 M | 61.8 M | |
| Net Debt | -82.5 M | -86.6 M | |
| Short Term Debt | 6.3 M | 3.5 M | |
| Net Debt To EBITDA | 0.36 | 0.65 | |
| Debt To Equity | 0.07 | 0.06 | |
| Interest Debt Per Share | 0.29 | 0.30 | |
| Debt To Assets | 0.06 | 0.05 | |
| Long Term Debt To Capitalization | 0.06 | 0.06 | |
| Total Debt To Capitalization | 0.06 | 0.06 | |
| Debt Equity Ratio | 0.07 | 0.06 | |
| Debt Ratio | 0.06 | 0.05 | |
| Cash Flow To Debt Ratio | (3.09) | (3.24) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Lyell Immunopharma Fundamentals Over Time. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.